For Patients
Management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Published in 2012 - Ann Oncol (2012) 23 (10): 2479-2516.
Authors: H. J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C. J. van de Velde, J. Balmana, J. Regula, I. D. Nagtegaal, R. G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J. Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes
For Patients
Onkologisches und Palliativmedizinisches Netzwerk
Career Development
NSCLC European Survey
In 2012, the Young Oncologists Committee carried out a Europe-wide survey about the use of adjuvant chemotherapy and radiotherapy in incompletely resected (R1) early stage Non-Small-Cell Lung Cancer (NSCLC). The project was led by Young Oncologists Committee member Raffaele Califano and presented as a poster during the ESMO 2012 Congress. Read the report.
For Patients
Vivantes Klinikum Spandau
Guidelines
Diffuse Large B-Cell Lymphoma
Published in 2015 – Ann Oncol (2015) 26 (suppl 5): v116-v125.
Authors: H. Tilly, M. Gomes da Silva, U. Vitolo, A. Jack, M. Meignan, A. Lopez-Guillermo, J. Walewski, M. André, P. W. Johnson, M. Pfreundschuh, M. Ladetto
Guidelines
Chemotherapy Extravasation
Published in 2012 – Ann Oncol 2012; 23 (Suppl 7): vii167-vii173.
Authors: J. A. Pérez Fidalgo, L. García Fabregat, A. Cervantes, A. Margulies, C. Vidall, F. Roila
Guidelines
Hepatocellular Carcinoma
Published in 2018 – Ann Oncol (2018) 29 (Suppl 4): iv238–iv255.
Authors: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold & E. Martinelli, on behalf of the ESMO Guidelines Committee
News
No gain from adding cetuximab to FOLFOX4 in patients with resected stage III colon cancer
PETACC8 study suggest a benefit in several patient subgroups
News
Treatment with bevacizumab beyond progression: A new standard in mCRC?
The addition of bevacizumab (BEV) to 5-FU-based chemotherapy has been a standard 1st-line treatment option for patients with metastatic colorectal cancer (mCRC) for many years, although the use of this agent beyond progression is an area of ongoing debate. However, emerging data suggest that this question may soon be answered